PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.37%
Cash & equivalents growing 13.37% while AXSM's declined -14.24%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
13.37%
Below half of AXSM's -14.24%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.78%
Below half of AXSM's -14.17%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.38%
Below half AXSM's -16.67%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Below half of AXSM's -13.84%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Below half of AXSM's -14.16%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.08%
Less than half of AXSM's -20.58%. David Dodd sees a more disciplined AP approach or lower volume.
2.29%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
8.08%
Higher Deferred Revenue (Current) Growth compared to AXSM's zero value, indicating better performance.
-2.29%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
-6.99%
Less than half of AXSM's 5.45%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.38%
Less than half of AXSM's 0.07%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-9.31%
Less than half of AXSM's 1.72%. David Dodd sees far fewer liability expansions relative to competitor.
10.53%
Above 1.5x AXSM's 0.24%. Michael Burry suspects heavy new equity expansion or dilution.
-2.12%
Below half AXSM's -10.48%. Michael Burry suspects major net losses or high dividends vs. competitor.
-7.96%
Higher AOCI Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
13.80%
Below half AXSM's -25.81%. Michael Burry sees potential underperformance in building shareholder capital.
12.46%
Below half AXSM's -14.16%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.56%
Above 1.5x AXSM's -0.14%. Michael Burry sees a major jump. Investigate leverage rationale.
-13.63%
Less than half of AXSM's 20.40%. David Dodd sees better deleveraging or stronger cash buildup than competitor.